Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
- Discovery efforts will focus on small molecules with differentiated clinical profiles to harness the broad potential of orexin agonism across different indications,
- First time Schrödinger is applying its computational platform in an orexin agonist setting enabled by Orexia’s structural biology capabilities.